{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164459","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.446122+00:00","generated_at":"2026-06-14T04:20:39.511874+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"AN2 Therapeutics stockholders elect three Class I directors and ratify PwC as auditor","bullets":["Elected Kabeer Aziz (14.78M for), Gilbert Lynn Marks (14.78M for), and Rob Readnour (14.61M for) as Class I directors.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2023: 16.56M for, 51.6K against.","Quorum of 16,610,548 shares (85.5% of outstanding) present at June 7, 2023 annual meeting.","Results based on proxy statement filed April 26, 2023; no other proposals voted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164459","json":"https://secwatch.observer/filing/0001193125-23-164459.json","markdown":"https://secwatch.observer/filing/0001193125-23-164459.md","text":"https://secwatch.observer/filing/0001193125-23-164459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/0001193125-23-164459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/d500763d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:20:39.511874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a610dcfc05a17eb7b5b41d50751a0e4296d33ef","claim":"AN2 Therapeutics, Inc. shareholders approved Election of three Class I directors: Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D. at the 2023-06-07 meeting.","evidence_excerpt":"1. To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2026 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Kabeer Aziz 14,783,208 747,428 1,079,912 16,610,548 Gilbert Lynn Marks, M.D. 14,781,503 749,133 1,079,912 16,610,548 Rob Readnour, Ph.D. 14,607,802 922,834 1,079,912 16,610,548","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/0001193125-23-164459-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"b3777b1829a592af182e3651a6748b669d2ce1f3","claim":"AN2 Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023. at the 2023-06-07 meeting.","evidence_excerpt":"2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting results were as follows: Votes For Votes Against Abstentions Total 16,558,919 51,629 0 16,610,548","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312523164459/0001193125-23-164459-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}